Ipsen Pharma Singapore PTE. LTD.

Ipsen Pharma Singapore PTE. LTD. is the Singaporean subsidiary of Ipsen, a global biopharmaceutical company founded in 1929. The parent group operates across 88 countries with a team of over 5,000 professionals, focusing on specialty care medicines in three therapeutic areas: Oncology, Rare Disease, and Neuroscience.

With a presence spanning the United States, France, the United Kingdom, and dozens of other markets, Ipsen navigates a complex regulatory landscape across multiple jurisdictions. The company's core business - research, development, and commercialisation of specialty pharmaceuticals - places it squarely within some of the most heavily regulated segments of the healthcare industry, involving drug approval processes, pharmacovigilance obligations, and cross-border data and trade compliance.

Ipsen has set an internal target of advancing at least one new molecular entity or meaningful indication per year, a pace of innovation that requires sustained investment in clinical development and regulatory submissions. The company describes its culture as defined by an entrepreneurial mindset, agility, and an impact-driven approach - qualities that, in a biopharmaceutical context, must be balanced against the rigorous controls demanded by global health authorities.